MDXG

MiMedx Group's stock price has been impacted by several events in the past six months, including Q4 2025 and Q1 2026 earnings reports, a restructuring and cost reduction initiative, revised 2026 revenue guidance, and product launches. The company reported mixed earnings results, announced cost-saving measures, significantly cut its 2026 revenue guidance due to reimbursement headwinds, and launched new products. Over the past 12 months, the stock has lost 47.1% of its value.